Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Journal of the American College of Cardiology © 2010 by the American College of Cardiology Foundation Published by Elsevier Inc. Vol. 55, No. 14, 2010 ISSN 0735-1097/10/$36.00 doi:10.1016/j.jacc.2009.09.072 Pre-Procedural Glucose Levels and the Risk for Contrast-Induced Acute Kidney Injury in Patients Undergoing Coronary Angiography Joshua M. Stolker, MD,*† Peter A. McCullough, MD, MPH,‡ Seshu Rao, MD,*† Silvio E. Inzucchi, MD,§ John A. Spertus, MD, MPH,*† Thomas M. Maddox, MD, MSC,储 Frederick A. Masoudi, MD, MSPH,¶ Lan Xiao, PHD,* Mikhail Kosiborod, MD*† Kansas City, Missouri; Royal Oak, Michigan; New Haven, Connecticut; and Denver, Colorado Objectives We sought to evaluate whether pre-procedural glucose levels are associated with contrast-induced acute kidney injury (CI-AKI) after coronary angiography. Background Although diabetes is a known risk factor for CI-AKI in patients undergoing coronary angiography, whether elevated preprocedural glucose levels (regardless of pre-existing diabetes) are associated with higher risk for CI-AKI is unknown. Methods We evaluated 6,358 patients with acute myocardial infarctions undergoing coronary angiography. Patients were stratified into 5 pre-procedural glucose groups: ⬍110 mg/dl, 110 to ⬍140 mg/dl, 140 to ⬍170 mg/dl, 170 to ⬍200 mg/dl, and ⱖ200 mg/dl. Logistic regression models were used to evaluate the relationship between glucose levels and risk for CI-AKI, first in the entire cohort and then in patients with and without established diabetes. The primary outcome was CI-AKI (ⱖ0.3 mg/dl absolute or ⱖ50% relative serum creatinine increase during 48 h after the procedure). Results The relationship between pre-procedural glucose and CI-AKI varied markedly in patients with and without diabetes. There was a strong association between glucose and CI-AKI risk in patients without diabetes (CI-AKI rates across the 5 glucose groups from lowest to highest: 8.2%, 9.9%, 12.4%, 14.9%, and 24.3%; p ⬍ 0.001), but not in patients with diabetes (20.9%, 16.1%, 16.3%, 14.8%, and 19.2%, respectively; p ⫽ 0.24; p for glucose ⫻ diabetes interaction ⬍0.001). After adjusting for confounders (including baseline glomerular filtration rate), the relationship between higher glucose and greater CI-AKI risk persisted in patients without diabetes (odds ratios [95% confidence intervals] for glucose groups of 110 to ⬍140 mg/dl, 140 to ⬍170, mg/dl 170 to ⬍200 mg/dl, and ⱖ200 mg/dl: 1.31 [1.00 to 1.71], 1.51 [1.11 to 2.10], 1.58 [1.03 to 2.43], and 2.14 [1.46 to 3.14] vs. glucose ⬍110 mg/dl, respectively), but this relationship was not seen in patients with established diabetes. Conclusions Elevated pre-procedural glucose is associated with greater risk for CI-AKI in patients without known diabetes who undergo coronary angiography in the setting of acute myocardial infarction. Measures used to prevent CIAKI should be considered in these patients. (J Am Coll Cardiol 2010;55:1433–40) © 2010 by the American College of Cardiology Foundation Contrast-induced acute kidney injury (CI-AKI) is a complication of coronary angiography that occurs commonly in the setting of acute myocardial infarction (AMI) (1,2) and is associated with severe adverse events, including permanent renal impairment (2– 4), higher in-hospital and long-term mortality (2,5–10), recurrent ischemic events (10,11), increased length of stay (2,12), and higher costs (13). Pro- From the *Mid America Heart Institute of Saint Luke’s Hospital, Kansas City, Missouri; †University of Missouri–Kansas City, Kansas City, Missouri; ‡William Beaumont Hospital, Royal Oak, Michigan; §Yale University and Yale-New Haven Hospital, New Haven, Connecticut; 储Denver VA Medical Center and University of Colorado Denver, Denver, Colorado; and the ¶Denver Health Medical Center and University of Colorado at Denver and Health Sciences Center, Denver, Colorado. The research for this analysis was supported by the American Heart Association Career Development Award in Implementation Research, awarded to Dr. Kosiborod. Dr. Stolker has received speaking honoraria from AstraZeneca Pharmaceuticals and Pfizer Pharmaceuticals; has served as a consultant to Novo Nordisk; and has served on the advisory board of Educational Testing Consultants, LLC. Dr. Inzucchi has received research grant support from Eli Lilly. Dr. Spertus has received research grant support from Sanofi-Aventis and Eli Lilly. Dr. Masoudi was previously a member of the advisory board of Takeda Pharmaceuticals. Dr. Kosiborod has served on the advisory board of Sanofi-Aventis and has received speaking honoraria from the Vascular Biology Working Group and DiaVed, Inc. The Cerner Corporation collected deidentified clinical information for the Health Facts database. The Cerner Corporation had no role in study design, data analysis, interpretation of findings, or writing of the manuscript. The American Heart Association had no role in the study. Manuscript received July 20, 2009; revised manuscript received September 9, 2009, accepted September 28, 2009. See page 1441 1434 Stolker et al. Glucose and Contrast-Induced Acute Kidney Injury posed pathophysiologic mechanisms through which contrast administration may potentiate renal AMI ⴝ acute myocardial injury include oxidative stress, free infarction radical damage, and endothelial CABG ⴝ coronary artery dysfunction (3,14,15). All of these bypass grafting processes also are activated in the CI-AKI ⴝ contrast-induced setting of hyperglycemia (3,16), acute kidney injury which is common in patients with GFR ⴝ glomerular filtration rate AMIs (17) and has adverse prognostic implications (16,18 –20), PCI ⴝ percutaneous coronary intervention particularly among those who do not have established diabetes (19 –21). Thus, it is possible that a combination of pre-procedural hyperglycemia and contrast exposure during coronary angiography could significantly increase the risk for CI-AKI. However, while diabetes is a well-recognized risk factor for CI-AKI (10,12,14), the association between preprocedural blood glucose levels and CI-AKI risk (regardless of pre-existing diabetes) is unknown. Since nearly 50% of hyperglycemic AMI patients do not have known diabetes (22), establishing whether elevated glucose levels before coronary angiography are related to subsequent CI-AKI risk would have important clinical implications; primarily by identifying a previously unrecognized high-risk group that might benefit from pre-procedural CI-AKI prophylaxis and also by highlighting a potential target for intervention in the prevention of CI-AKI. Accordingly, we analyzed data from the Cerner Corporation’s (Kansas City, Missouri) Health Facts database, a contemporary registry of patients admitted to 40 hospitals across the U.S., to define the association between preprocedural hyperglycemia and the risk for CI-AKI during AMI. This database was selected because of its extensive collection of laboratory data, including detailed glucose measurements and assessments of renal function, in a large consecutive cohort of AMI patients. We specifically sought to determine the relationship between pre-procedural glucose levels and the risk for subsequent CI-AKI among patients with and without known diabetes who are referred for coronary angiography in the setting of AMI. Abbreviations and Acronyms Methods Data source. Details of the Health Facts database have been described previously (22). Between January 1, 2000, and December 31, 2005, the Health Facts database collected deidentified information regarding consecutive patients hospitalized at 40 U.S. medical centers. Variables included demographics, medical history, and comorbidities (determined from International Classification of DiseasesNinth Revision billing codes), laboratory studies (including all venous and fingerstick blood glucose measurements, as well as all serum creatinine levels during hospitalization), medications, in-hospital procedures (including coronary JACC Vol. 55, No. 14, 2010 April 6, 2010:1433–40 angiography and percutaneous coronary intervention [PCI]), in-hospital mortality, and hospital characteristics (geographic region, number of beds, surgical and procedural capabilities, and teaching vs. nonteaching status). Patient population. We identified all patients hospitalized with primary discharge diagnoses of AMI (using International Classification of Diseases-Ninth Revision-Clinical Modification codes 410.xx and excluding 410.x2, which represents readmission after AMI) who had glucose measurements on admission and at least 1 documented abnormal troponin or creatine kinase-myocardial band level. Subsequently, those patients who were transferred from or to other acute care facilities were excluded, as complete laboratory and medication administration details for the entire episode of AMI care were not available. For this analysis, we further restricted the sample to those who underwent coronary angiography during the AMI hospitalization and whose laboratory studies included at least 1 pre-procedural measurement of serum creatinine and at least 1 repeat evaluation within 48 h after the procedure. Of 8,786 AMI patients who underwent coronary angiography during the index hospitalization, 6,358 patients (72%) had complete pre- and post-procedural laboratory data and comprised the study cohort. Glucose assessment and diabetes definition. The Health Facts database provided access to all of the patients’ glucose values, including their measurement times. For clarity, all plasma and capillary glucose measurements are subsequently referred to as “blood glucose.” The glucose level evaluated for each patient was the pre-procedural measurement obtained closest to the time of diagnostic angiography. As in prior studies (22–24), patients were classified as having recognized diabetes if they had corresponding International Classification of Diseases-Ninth Revision-Clinical Modification codes or were treated with an oral antihyperglycemic agent or any extended-release insulin during the hospitalization. Outcomes. The outcome for this study was the occurrence of CI-AKI, defined as an absolute serum creatinine increase ⱖ0.3 mg/dl or a relative increase in serum creatinine ⱖ50% that occurred within 48 h after coronary angiography, in accordance with the Acute Kidney Injury Network criteria (25). The rates of CI-AKI were calculated using pre- and post-procedural serum creatinine measurements. Preprocedural serum creatinine level was defined as the measurement obtained during hospitalization that occurred before and closest to the time of coronary angiography. Post-procedural creatinine level was defined as the highest serum creatinine measurement within 48 h after coronary angiography. If a patient underwent more than 1 coronary angiography procedure, pre- and post-procedural creatinine levels for the first procedure were considered for this analysis. Statistical analysis. Patients were stratified into 5 groups according to pre-procedural glucose levels: ⬍110 mg/dl, 110 to ⬍140 mg/dl, 140 to ⬍170 mg/dl, 170 to ⬍200 Stolker et al. Glucose and Contrast-Induced Acute Kidney Injury JACC Vol. 55, No. 14, 2010 April 6, 2010:1433–40 mg/dl, and ⱖ200 mg/dl. Baseline characteristics were compared among groups using chi-square analysis for categorical variables and analysis of variance for continuous variables. Rates of CI-AKI were compared between subgroups of pre-procedural glucose levels using chi-square analysis, first in the entire sample and then within the a priori defined subgroups of patients with and without known diabetes. Multivariable logistic regression models were subsequently developed to evaluate whether the association between pre-procedural glucose values and CI-AKI persisted after adjustment for other patient characteristics and potential confounders. In these models, pre-procedural glucose level was included as a categorical variable, using the 5 groups described previously. Patient characteristics clinically considered to be prognostically important, and covariates identified in bivariate analyses as predictors of CI-AKI (at a level of significance of p ⱕ 0.05), were entered into the models. Covariates included demographic factors (age, gender, and race), comorbidities (diabetes, heart failure, hypertension, and cerebrovascular disease), laboratory values (admission hematocrit and peak troponin value), mechanical reperfusion during hospitalization (coronary artery bypass grafting [CABG] or PCI), medications during hospitalization (aspirin, clopidogrel, ticlopidine, beta-blockers, calciumchannel blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors, oral antihyperglycemic agents, and insulin), hospital site, and hospital length of stay. A pre-procedural glucose ⫻ diabetes interaction term was also introduced into the models to formally test whether the glucose-associated risk for CIAKI differed in patients with and without known diabetes. Importantly, the models also adjusted for the baseline estimated glomerular filtration rate (GFR), calculated according to the Modification of Diet in Renal Disease study equation (26). Because contrast volume is a significant factor in the development of CI-AKI (1), models adjusted for the performance of PCI (categorized as none, single vessel, or multivessel), as well as the number of coronary angiography and PCI procedures during hospitalization (all surrogates of contrast volume). In addition, to account for pre-procedural CI-AKI prophylaxis measures, the final models also adjusted for the administration of sodium bicarbonate. Models were then repeated within the subgroups of patients with and without diabetes. Several sensitivity analyses were performed. First, multivariable models were repeated after excluding all patients who underwent CABG within 48 h of coronary angiography, to ensure that our results were not confounded by the potential impact of CABG on renal function. Second, cardiogenic shock was incorporated as a covariate into the models, given its associations with both hyperglycemia and CI-AKI (2,19). Third, a different definition of CI-AKI was used (increase in serum creatinine ⬎0.5 mg/dl or ⬎25%). 1435 Secondary analyses. Additional analyses were performed to examine whether the relationship between pre-procedural glucose levels and CI-AKI differed according to baseline renal function. To accomplish this, patients were divided into 3 groups according to baseline GFR (⬍30 ml/min, 30 to 59 ml/min, and ⱖ60 ml/min). The rates of CI-AKI were then compared across the 5 pre-procedural glucose categories (⬍110 mg/dl, 110 to ⬍140 mg/dl, 140 to ⬍170 mg/dl, 170 to ⬍200 mg/dl, and ⱖ200 mg/dl) within each of the GFR subclasses, using chi-square analysis. These analyses were then performed separately in patients with and without diabetes. A 2-sided p value of ⱕ0.05 was considered statistically significant. Analyses were conducted with SAS version 8.02 (SAS Institute Inc., Cary, North Carolina). Use of the Health Facts database was approved by the Saint Luke’s Mid America Heart Institute Institutional Review Board. Results Baseline characteristics. Baseline characteristics are detailed in Table 1, stratified by pre-procedural glucose levels. Pre-procedural hyperglycemia (glucose ⱖ140 mg/dl) occurred in 42% of the patient sample, and 48% of patients with elevated glucose before coronary angiography did not have known diabetes. The median time from pre-procedural glucose assessment to coronary angiography was 8.3 h (interquartile range: 5.3 to 16.3 h). Diabetes was present in 1,929 patients (30%). Overall, 823 patients (13%) developed CI-AKI after coronary angiography. Mean creatinine in these patients increased from 1.73 ⫾ 1.5 mg/dl at baseline to a peak of 2.54 ⫾ 1.8 mg/dl, whereas patients without CI-AKI experienced no significant change in serum creatinine (baseline: 1.16 ⫾ 0.8 mg/dl; post-procedure: 1.14 ⫾ 0.7 mg/dl). The median number of post-procedural creatinine measurements was 1 for patients with glucose ⬍110 mg/dl and 2 in all other glucose groups. The median number of coronary angiograms performed during AMI hospitalization was 1, and the median number of PCI procedures during hospitalization was 1 across all 5 of the glucose groups. Overall, 43% of all patients underwent diagnostic coronary angiography only, 50% underwent single-vessel PCI, and 7% underwent multivessel PCI. Median hospital length of stay was 113 h (interquartile range: 74 to 193 h) and is stratified by glucose level in Table 1. Compared with patients who had lower pre-procedural glucose, greater proportions of those with higher glucose were female and had prior heart failure, AMIs, and diabetes. Hyperglycemic patients also had lower GFRs, had higher peak troponin levels and lower hematocrit on admission, and were treated more frequently with diuretics, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, oral antihyperglycemic agents, and insulin. Periprocedural infusions of sodium bicarbonate, in-hospital PCI, and in-hospital CABG were used more frequently in patients with higher glucose levels. Stolker et al. Glucose and Contrast-Induced Acute Kidney Injury 1436 JACC Vol. 55, No. 14, 2010 April 6, 2010:1433–40 Stratified Characteristics Baseline by Baseline Pre-Procedural of AMI Glucose Patients Concentration Undergoing Angiography (n ⴝ 6,358),(n ⴝ 6,358), Characteristics of AMI Patients Coronary Undergoing Coronary Angiography Table 1 Stratified by Pre-Procedural Glucose Concentration Glucose Concentration (mg/dl) Characteristic <110 (n ⴝ 1,814) 110–<140 (n ⴝ 1,891) 140–<170 (n ⴝ 1,086) 170–<200 (n ⴝ 533) >200 (n ⴝ 1,034) p Value Demographics Age (yrs) 64 ⫾ 14 64 ⫾ 13 66 ⫾ 13 66 ⫾ 12 65 ⫾ 12 0.002 671 (37) 588 (31) 411 (38) 199 (37) 442 (43) ⬍0.001 1,472 (84) 1,598 (87) 897 (85) 458 (88) 843 (84) 0.024 Hypertension 973 (54) 993 (53) 598 (55) 314 (59) 533 (52) 0.047 Diabetes 225 (12) 311 (16) 344 (32) 278 (52) 771 (75) ⬍0.001 Chronic obstructive lung disease 206 (11) 176 (9) 108 (10) 45 (8) 102 (10) 0.187 Prior AMI 205 (11) 236 (12) 99 (9) 42 (8) 113 (11) 0.008 Prior heart failure 404 (22) 413 (22) 306 (28) 172 (32) 410 (40) ⬍0.001 50 (3) 38 (2) 27 (2) 19 (4) 33 (3) 0.189 110 (6) 96 (5) 58 (5) 31 (6) 39 (4) 0.115 Female White Medical history Prior stroke Peripheral vascular disease In-hospital medications Aspirin 1,609 (89) 1,669 (88) 939 (86) 459 (86) 879 (85) 0.026 Other antiplatelet agent 1,218 (67) 1,365 (72) 766 (71) 368 (69) 697 (67) 0.008 Beta-blocker 1,632 (90) 1,711 (90) 975 (90) 470 (88) 901 (87) 0.049 ACE inhibitor or ARB 1,205 (66) 1,331 (70) 786 (72) 397 (74) 763 (74) ⬍0.001 Calcium-channel blocker 411 (23) 402 (21) 203 (19) 119 (22) 249 (24) 0.033 Diuretic 751 (41) 799 (42) 494 (45) 298 (56) 614 (59) ⬍0.001 0.207 Nitrate 1,467 (81) 1,565 (83) 888 (82) 453 (85) 857 (83) Statin 1,226 (68) 1,309 (69) 755 (70) 363 (68) 714 (69) 0.777 67 (4) 86 (5) 121 (11) 107 (20) 260 (25) ⬍0.001 271 (15) 327 (17) 283 (26) 212 (40) 620 (60) ⬍0.001 Leukocyte count (⫻1,000/l) 10 ⫾ 4 10 ⫾ 7 11 ⫾ 4 11 ⫾ 6 11 ⫾ 4 ⬍0.001 Hematocrit (%) 36 ⫾ 14 39 ⫾ 12 38 ⫾ 11 38 ⫾ 10 38 ⫾ 12 ⬍0.001 1.26 ⫾ 1.07 1.20 ⫾ 0.84 1.22 ⫾ 0.81 1.35 ⫾ 1.02 1.38 ⫾ 1.09 ⬍0.001 Estimated GFR (ml/min) 75 ⫾ 30 75 ⫾ 27 71 ⫾ 28 68 ⫾ 29 67 ⫾ 31 ⬍0.001 Peak troponin (ng/ml) 48 ⫾ 164 74 ⫾ 127 78 ⫾ 126 74 ⫾ 133 92 ⫾ 240 ⬍0.001 Oral antihyperglycemic agent Any insulin Laboratory studies Baseline creatinine (mg/dl) In-hospital management Cardiogenic shock 24 (1) 46 (2) 68 (6) 37 (7) 118 (11) ⬍0.001 Intra-aortic balloon pump 73 (4) 109 (6) 98 (9) 51 (10) 141 (14) ⬍0.001 822 (45) 1,030 (55) 572 (53) 262 (49) 511 (49) ⬍0.001 PCI Single-vessel 117 (7) 124 (7) 83 (8) 33 (6) 73 (7) CABG Multivessel 277 (15) 275 (15) 169 (16) 103 (19) 183 (18) 0.034 Sodium bicarbonate infusion 251 (14) 271 (14) 173 (16) 94 (18) 243 (24) ⬍0.001 117 (75–188) 104 (69–181) 109 (73–197) 131 (83–212) ⬍0.001 Hospital length of stay (h), median (IQR) 130 (82–213) Categorical variables are expressed as n (%) and continuous variables as mean ⫾ SD, unless otherwise stated. ACE ⫽ angiotensin-converting enzyme; AMI ⫽ acute myocardial infarction; ARB ⫽ angiotensin receptor blocker; CABG ⫽ coronary artery bypass grafting; GFR ⫽ glomerular filtration rate (by Modification of Diet in Renal Disease study equation); IQR ⫽ interquartile range; PCI ⫽ percutaneous coronary intervention. Pre-procedural glucose and CI-AKI. In unadjusted analyses, higher pre-procedural glucose levels were strongly associated with higher rates of CI-AKI (Table 2). However, the nature of the relationship between glucose levels and CI-AKI was significantly different in patients with and without known diabetes (pre-procedural glucose ⫻ diabetes interaction p ⬍ 0.001). There was a strong association between glucose and CI-AKI risk in patients without diabetes (CI-AKI rates across the 5 glucose groups from lowest to highest: 8.2%, 9.9%, 12.4%, 14.9%, and 24.3%; p ⬍ 0.001). In contrast, no significant relationship was observed between glucose levels and CI-AKI in patients with established diabetes (CI-AKI rates across the 5 glucose groups from lowest to highest: 20.9%, 16.1%, 16.3%, 14.8%, and 19.2%; p ⫽ 0.24). After adjusting for confounders (including baseline GFR), the nature of these relationships between glucose levels and CI-AKI risk persisted (Fig. 1). In patients without known diabetes, there was a gradual, incremental increase in the risk for CI-AKI associated with higher pre-procedural glucose levels (odds ratios [95% confidence intervals] for glucose groups of 110 to ⬍140 mg/dl, 140 to ⬍170 mg/dl, 170 to ⬍200 mg/dl, and ⱖ200 mg/dl: 1.31 [1.00 to 1.71], 1.51 [1.11 to 2.10], 1.58 [1.03 to 2.43], and 2.14 [1.46 to 3.14], respectively, vs. glucose ⬍110 mg/dl). Stolker et al. Glucose and Contrast-Induced Acute Kidney Injury JACC Vol. 55, No. 14, 2010 April 6, 2010:1433–40 1437 Unadjusted of CI-AKI According Pre-Procedural Glucose Level Table 2 Rates Unadjusted Rates of CI-AKItoAccording to Pre-Procedural Glucose Level Glucose Level (mg/dl) Patient Subgroup <110 110–<140 140–<170 170–<200 >200 p Value Entire cohort 177/1,814 (9.8) 207/1,891 (11.0) 148/1,086 (13.6) 79/533 (14.8) 212/1,034 (20.5) ⬍0.001 Patients without known diabetes 130/1,589 (8.2) 157/1,580 (9.9) Patients with known diabetes 47/225 (20.9) 50/311 (16.1) 92/742 (12.4) 38/255 (14.9) 64/263 (24.3) ⬍0.001 56/344 (16.3) 41/278 (14.8) 148/771 (19.2) 0.24* Values are expressed as n (%) of patients experiencing CI-AKI. *Interaction term for pre-procedural glucose and diabetes: p ⬍ 0.001. CI-AKI ⫽ contrast-induced acute kidney injury. However, no significant increase in glucose-associated risk for CI-AKI was seen among patients with established diabetes (corresponding odds ratios [95% confidence intervals]: 0.71 [0.44 to 1.14], 0.82 [0.52 to 1.30], 0.73 [0.45 to 1.12], and 0.94 [0.63 to 1.40]; adjusted p value for glucose ⫻ diabetes interaction ⫽ 0.04). In 3 sensitivity analyses— first excluding patients who underwent CABG within 48 h of coronary angiography, second adjusting for the rates of cardiogenic shock, and third using a different definition of CI-AKI—the results were similar (data not shown). Secondary analyses. Among patients without known diabetes, the relationship between pre-procedural glucose levels and the risk for CI-AKI differed according to baseline GFR (Fig. 2). There was a graded, significant relationship between higher pre-procedural glucose levels and greater risk for CI-AKI in patients with GFR ⱖ60 ml/min (CI-AKI rates across the 5 glucose groups from lowest to highest: 6%, 7%, 9%, 10%, and 18%; p ⬍ 0.001) and in those with GFRs of 30 to 59 ml/min (11%, 16%, 19%, 18%, and 27%, respectively; p ⫽ 0.003). However, the relationship between glucose and CI-AKI was not significant among patients with severely impaired renal function (GFR ⬍30 ml/min), as risk remained high regardless of glucose level (CI-AKI rates across the 5 glucose groups from lowest to highest: 39%, 30%, 33%, 44%, and 44%; p ⫽ 0.66). Figure 1 Among patients with established diabetes, there was no significant association between pre-procedural glucose levels and CI-AKI rates in any of the GFR subgroups (data not shown). Discussion In this large sample of AMI patients undergoing coronary angiography, we found that the nature of the relationship between pre-procedural glucose levels and the risk for CI-AKI was markedly different among patients with and without established diabetes. Elevated glucose was common and associated with a steep incremental increase in the risk for CI-AKI after coronary angiography among patients who did not have known diabetes. In contrast, no such association was observed among patients with established diabetes, who experienced high CI-AKI rates regardless of preprocedural glucose levels. Importantly, glucose-associated CI-AKI risk was as high or even higher in patients without diabetes who had significant pre-procedural hyperglycemia, as in those with established diabetes. Moreover, the relationship between higher pre-procedural glucose and greater CI-AKI risk was particularly pronounced in those patients without diabetes who did not have significantly impaired renal function, a group that is not currently considered to be at high risk for CI-AKI. Our findings imply that, at a Glucose and Risk of CI-AKI Relationship between pre-procedural glucose levels and risk for contrast-induced acute kidney injury (CI-AKI) after coronary angiography in acute myocardial infarction patients with and without known diabetes after multivariate adjustment. CI ⫽ confidence interval. 1438 Figure 2 Stolker et al. Glucose and Contrast-Induced Acute Kidney Injury JACC Vol. 55, No. 14, 2010 April 6, 2010:1433–40 Glucose and CI-AKI Rates Across GFR Subgroups Relationship between pre-procedural glucose levels and contrast-induced acute kidney injury (CI-AKI) across subgroups of glomerular filtration rate (GFR) (calculated using the Modification of Diet in Renal Disease study equation) in patients without known diabetes. minimum, hyperglycemic patients without known diabetes should be recognized as a high-risk group for CI-AKI and should be considered for prophylactic measures similar to those used in other high-risk patients. Prior studies of hyperglycemia. This study is the first, to our knowledge, to demonstrate that elevated pre-procedural glucose levels are associated with increased risk for CI-AKI in AMI patients without diabetes undergoing coronary angiography. However, the relationship between hyperglycemia and renal injury has been previously described in other patient populations. Specifically, prior studies have demonstrated a relationship between higher glucose levels and greater risk for acute renal failure among critically ill patients hospitalized in intensive care units (27). Elevated pre- and perioperative glucose levels are also independently associated with higher risk for post-operative renal dysfunction among patients undergoing cardiac surgery (28,29); in fact, pre-operative glucose ⬎140 mg/dl has been incorporated into a prediction model of post-operative kidney injury in this patient population (28). A few relatively small, single-center studies also suggested that pre-diabetes may increase the risk for contrast-induced nephropathy in patients with chronic kidney disease who undergo elective coronary angiography (30) and that metabolic syndrome may increase the risk for acute renal failure in patients with AMIs (31). Our study adds substantially to these data by demonstrating in a large, multicenter cohort that preprocedural hyperglycemia markedly elevates the risk for CI-AKI in patients without established diabetes, even after accounting for baseline renal function and a multitude of other factors. Clinical implications. Our findings have several potentially important clinical implications. First, although diabetes is a well-known predictor of contrast nephropathy (10,12,14), elevated pre-procedural glucose levels in patients without established diabetes are not currently recognized by clinicians as a risk factor for contrast-mediated renal injury. Since hyperglycemia occurs in over 40% of AMI patients, nearly half of whom have no known diabetes (19,22,32), this group of patients should at least be considered to be at as high a risk for CI-AKI as those with established diabetes. CI-AKI prophylaxis may need to be considered in these patients, as well as careful monitoring of post-procedural renal function. Second, elevated pre-procedural glucose may represent a modifiable intervention target for CI-AKI prevention. Whether hyperglycemia is a marker of increased comorbidity burden and disease severity or a direct mediator of CI-AKI is unknown, but prior studies have demonstrated increased oxidative stress, blunting of free radical scavengers, decreased levels of nitric oxide, and endothelial dysfunction in the setting of elevated glucose (33– 42). Other investigators have shown enhanced susceptibility to ischemic and reperfusion injury in animal models of experimentally induced hyperglycemia (43). Since numerous studies have shown that similar pathophysiologic mechanisms are also involved in contrast nephropathy (3,14,15), the effects of hyperglycemia in our analysis may reflect a “double insult” to renal function that previously has not been described in patients without established diabetes. Although no conclusions regarding a possible cause-and-effect relationship between hyperglycemia and CI-AKI can be drawn from our study, several randomized trials in critically ill patients have demonstrated that glycemic control with insulin may reduce the rates of acute renal failure (44 – 46). Because the findings of these clinical trials cannot be automatically extrapolated to AMI patients undergoing coronary angiography, prospective randomized studies are needed to determine whether glucose control can reduce the rates of CI-AKI in the setting of AMI. The reasons behind the different relationships between glucose levels and CI-AKI risk among patients with and without known diabetes are unclear but have been previously described with other outcomes, such as mortality (19 –22). Several possible explanations exist for this phenomenon. First, as previously demonstrated in other studies (19,32), hyperglycemic AMI patients without known dia- JACC Vol. 55, No. 14, 2010 April 6, 2010:1433–40 betes typically receive much less aggressive therapy for glucose control compared with those who have known diabetes. Since intensive glucose control with insulin has been previously shown to reduce the rates of renal injury in critically ill patients (44,46,47), this significant discrepancy in treatment rates may have an effect on glucose-associated CI-AKI rates. Second, since diabetes is a well-recognized risk factor for CI-AKI, patients with diabetes may receive more aggressive pre-procedural CI-AKI prophylaxis, attenuating the potential effect of hyperglycemia on renal injury. Third, some hyperglycemic AMI patients without known diabetes (particularly those with glucose ⬎200 mg/dl) may actually have diabetes that has been neither recognized nor adequately managed and thus may represent a higher-risk cohort for the development of CI-AKI. Even if not definitively diagnosed with diabetes by hospital discharge, hyperglycemia in AMI patients likely represents glucose dysmetabolism, and the simple act of evaluating pre-catheterization glucose should alert clinicians to the elevated risk for renal injury. Finally, it is also possible that a greater degree of stress (illness severity) is needed for patients without established diabetes to achieve the same degree of hyperglycemia as their counterparts with diabetes. However, the difference in the association between hyperglycemia and CI-AKI among patients with and without known diabetes persisted even after accounting for disease severity indicators, including infarct size. Study limitations. The results of our study should be interpreted in the context of several potential limitations. First, the volume of contrast administered in each procedure was not available; however, we believe that by using the performance of PCI (including the differentiation between single-vessel and multivessel PCI) in the multivariable models, we introduced a surrogate for presumed higher contrast volume (compared with diagnostic angiography alone). Moreover, there is no a priori reason to expect that hyperglycemic patients would be more likely to receive larger or smaller doses of contrast material than normoglycemic patients. Second, although we rigorously attempted to account for baseline differences between patients in different pre-procedural glucose groups, residual confounding cannot be excluded. Specifically, we were unable to control for certain clinical variables, such as the presence of ST-segment elevation and left ventricular ejection fraction. However, adjustment for ST-segment elevation and ejection fraction did not affect the nature of glucose-associated risk for mortality in our prior studies (19), and we were able to control for other variables, such as infarct size (using peak troponin levels) and numerous other patient factors. Third, our data are limited to AMI patients undergoing angiography, and the relationship between hyperglycemia and CIAKI in other patient populations or with other diagnostic modalities requiring intravenous contrast (e.g., computed tomography scans, other angiograms) remains unclear. Fourth, we do not know how many of those patients without known diabetes were subsequently diagnosed with Stolker et al. Glucose and Contrast-Induced Acute Kidney Injury 1439 diabetes after discharge; however, our specific focus was to evaluate the CI-AKI risk associated with pre-procedural glucose values in patients who were not recognized as having diabetes at the time of AMI hospitalization. Finally, although we adjusted for sodium bicarbonate administration in our analyses, we were unable to determine whether glucose lowering with insulin or the use of other prophylactic CI-AKI therapies (e.g., intravenous hydration or N-acetylcysteine) could reduce the risk for CI-AKI in hyperglycemic AMI patients without established diabetes. This will need to be determined in future prospective investigations. Conclusions In summary, elevated pre-procedural glucose levels are associated with greater risk for CI-AKI in AMI patients without established diabetes who undergo coronary angiography. Close monitoring of post-procedural renal function and prophylactic therapies used to prevent CI-AKI should be considered in this patient group. Reprint requests and correspondence: Dr. Mikhail Kosiborod, Mid America Heart Institute of Saint Luke’s Hospital, 4401 Wornall Road, Kansas City, Missouri 64111. E-mail: [email protected]. REFERENCES 1. Marenzi G, Assanelli E, Campodonico J, et al. Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. Ann Intern Med 2009; 150:170 –7. 2. Marenzi G, Lauri G, Assanelli E, et al. Contrast-induced nephropathy in patients undergoing primary angioplasty for acute myocardial infarction. J Am Coll Cardiol 2004;44:1780 –5. 3. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. CMAJ 2005;172: 1461–71. 4. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. Am J Cardiol 2004;94:300 –5. 5. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996;275:1489 –94. 6. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002;105:2259 – 64. 7. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. Am J Med 1997;103:368 –75. 8. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000;36:1542– 8. 9. Sadeghi HM, Stone GW, Grines CL, et al. Impact of renal insufficiency in patients undergoing primary angioplasty for acute myocardial infarction. Circulation 2003;108:2769 –75. 10. Lindsay J, Apple S, Pinnow EE, et al. Percutaneous coronary intervention-associated nephropathy foreshadows increased risk of late adverse events in patients with normal baseline serum creatinine. Catheter Cardiovasc Interv 2003;59:338 – 43. 11. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study. Circulation 1999;99:2626 –32. 1440 Stolker et al. Glucose and Contrast-Induced Acute Kidney Injury 12. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005;95: 13–9. 13. Subramanian S, Tumlin J, Bapat B. Economic burden of contrastinduced nephropathy: Implications for prevention strategies. J Med Econ 2007;10:119 –34. 14. McCullough PA. Acute kidney injury with iodinated contrast. Crit Care Med 2008;36:S204 –11. 15. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol 2006;98 Suppl:27K–36K. 16. Deedwania P, Kosiborod M, Barrett E, et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008;117:1610 –9. 17. Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140 – 4. 18. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355: 773– 8. 19. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005;111:3078 – 86. 20. Stranders I, Diamant M, van Gelder RE, et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 2004; 164:982– 8. 21. Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol 2002;40:1748 –54. 22. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucometrics in patients hospitalized with acute myocardial infarction: defining the optimal outcomes-based measure of risk. Circulation 2008;117: 1018 –27. 23. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 2009;301: 1556 – 64. 24. Kosiborod M, Inzucchi SE, Krumholz HM, et al. Glucose normalization and outcomes in patients with acute myocardial infarction. Arch Intern Med 2009;169:438 – 46. 25. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31. 26. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461–70. 27. Cheung NW, Napier B, Zaccaria C, Fletcher JP. Hyperglycemia is associated with adverse outcomes in patients receiving total parenteral nutrition. Diabetes Care 2005;28:2367–71. 28. Palomba H, de Castro I, Neto AL, Lage S, Yu L. Acute kidney injury prediction following elective cardiac surgery: AKICS score. Kidney Int 2007;72:624 –31. JACC Vol. 55, No. 14, 2010 April 6, 2010:1433–40 29. Gandhi GY, Nuttall GA, Abel MD, et al. Intraoperative hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clin Proc 2005;80:862– 6. 30. Toprak O, Cirit M, Yesil M, et al. Impact of diabetic and pre-diabetic state on development of contrast-induced nephropathy in patients with chronic kidney disease. Nephrol Dial Transplant 2007;22:819 –26. 31. Clavijo LC, Pinto TL, Kuchulakanti PK, et al. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovasc Revasc Med 2006;7:7–11. 32. Kosiborod M, Inzucchi S, Clark B, et al. National patterns of glucose control among patients hospitalized with acute myocardial infarction. J Am Coll Cardiol 2007;49:283A. 33. Bohlen HG, Lash JM. Topical hyperglycemia rapidly suppresses EDRF-mediated vasodilation of normal rat arterioles. Am J Physiol 1993;265:H219 –25. 34. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991;87:432– 8. 35. Catherwood MA, Powell LA, Anderson P, McMaster D, Sharpe PC, Trimble ER. Glucose-induced oxidative stress in mesangial cells. Kidney Int 2002;61:599 – 608. 36. Giugliano D, Marfella R, Coppola L, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine. Evidence for reduced availability of nitric oxide during hyperglycemia. Circulation 1997;95:1783–90. 37. Marfella R, Quagliaro L, Nappo F, Ceriello A, Giugliano D. Acute hyperglycemia induces an oxidative stress in healthy subjects. J Clin Invest 2001;108:635– 6. 38. Marfella R, Verrazzo G, Acampora R, et al. Glutathione reverses systemic hemodynamic changes induced by acute hyperglycemia in healthy subjects. Am J Physiol 1995;268:E1167–73. 39. Tesfamariam B, Cohen RA. Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992;263: H321– 6. 40. Trachtman H, Futterweit S, Crimmins DL. High glucose inhibits nitric oxide production in cultured rat mesangial cells. J Am Soc Nephrol 1997;8:1276 – 82. 41. Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998;97:1695–701. 42. Marfella R, Nappo F, De Angelis L, Paolisso G, Tagliamonte MR, Giugliano D. Hemodynamic effects of acute hyperglycemia in type 2 diabetic patients. Diabetes Care 2000;23:658 – 63. 43. Melin J, Hellberg O, Fellstrom B. Hyperglycaemia and renal ischaemia-reperfusion injury. Nephrol Dial Transplant 2003;18: 460 –2. 44. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359 – 67. 45. Schetz M, Vanhorebeek I, Wouters PJ, Wilmer A, Van den Berghe G. Tight blood glucose control is renoprotective in critically ill patients. J Am Soc Nephrol 2008;19:571– 8. 46. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449 – 61. 47. Thomas G, Rojas MC, Epstein SK, Balk EM, Liangos O, Jaber BL. Insulin therapy and acute kidney injury in critically ill patients a systematic review. Nephrol Dial Transplant 2007;22:2849 –55. Key Words: contrast nephropathy y acute kidney injury y glucose y diabetes y myocardial infarction y coronary angiography.